Study of BL-B01D1 plus immunotherapy for extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug combination—BL-B01D1 plus a PD-1 immunotherapy—for people who have just been diagnosed with extensive-stage small cell lung cancer and have not had any prior treatment for it. The goal is to see if this combination can help shrink or control the cancer better than standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have just been diagnosed with extensive-stage small cell lung cancer (cancer that has spread beyond one lung).
- You are between 18 and 75 years old and are able to do daily activities on your own (ECOG score 0 or 1).
- You have not yet received any anti-cancer treatment for your extensive-stage disease.
- You have a tumor sample (from a past biopsy or a new one) available for testing.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study and for 6 months after.
- You do not have active autoimmune diseases, uncontrolled infections, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (BL-M14D1 and Atezolizumab) for people with extensive-stage small cell lung cancer that has not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow the growth of the cancer.
This trial tests a new drug combination (BL-B01D1 plus immunotherapy) as a first treatment for people with advanced small cell lung cancer. It may be an option if you haven't had treatment yet and are healthy enough for chemotherapy.
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
This trial tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) against a standard chemo/immu-notherapy combination. It is for people with previously untreated, advanced triple-negative breast cancer whose tumors have a protein called PD-L1.
This trial tests a new drug, BL-M14D1, for people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have no standard treatment. The goal is to see if the drug is safe and possibly effective.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.